Within the previous decade, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has been recognized to play a critical role in sepsis pathobiology.4,5PCSK9 loss-of-function (LOF) or pharmacologic inhibition has been demonstrated to result in increased hepatocyte low-density lipoprotein receptor (LDLR) mediated bacterial and endotoxin clearance.6,7 Based on these data, ongoing clinical trials will test the efficacy of commercially available PCSK9 inhibitors as novel sepsis therapeutics (NCT03869073 and NCT03634293). This evidence concerns the gene LDLR and Sepsis.